Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-03-19
2011-12-06
Rao, Manjunath (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S069200
Reexamination Certificate
active
08071551
ABSTRACT:
The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α1-antitrypsin or an α1-antitrypsin-like agent, including, but not limited to oxidation-resistant variants of α1-antitrypsin, and peptoids with antitrypsin activity. The diseases treatable by the invention include cancer, autoimmune disease, sepsis neurodegenerative disease, myocardial infarction, stroke, ischemia-reperfusion injury, toxin induced liver injury and AIDS. The method of the invention is also suitable for the prevention or amelioration of diseases characterized by excessive apoptosis.
REFERENCES:
patent: 4629567 (1986-12-01), Bollen et al.
patent: 4711848 (1987-12-01), Insley et al.
patent: 4829054 (1989-05-01), Emerson et al.
patent: 5040545 (1991-08-01), Dutcher et al.
patent: 5134119 (1992-07-01), Lezdey et al.
patent: 5187089 (1993-02-01), Scott et al.
patent: 5216022 (1993-06-01), Oleksyszyn et al.
patent: 5314910 (1994-05-01), Kirschenheuter et al.
patent: 5346886 (1994-09-01), Lezdey et al.
patent: 5376655 (1994-12-01), Imaki et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5416191 (1995-05-01), Cheronis et al.
patent: 5420110 (1995-05-01), Miller et al.
patent: 5432178 (1995-07-01), Nakai et al.
patent: 5470970 (1995-11-01), Saeger et al.
patent: 5476995 (1995-12-01), Clark et al.
patent: 5478727 (1995-12-01), Roizman et al.
patent: 5486470 (1996-01-01), Darke et al.
patent: 5492889 (1996-02-01), Lezdey et al.
patent: 5514653 (1996-05-01), Perlmutter
patent: 5514713 (1996-05-01), Nakai et al.
patent: 5529920 (1996-06-01), Cole et al.
patent: 5532215 (1996-07-01), Lezdey et al.
patent: 5565334 (1996-10-01), Kufe et al.
patent: 5593858 (1997-01-01), Fleer et al.
patent: 5604201 (1997-02-01), Thomas et al.
patent: 5610140 (1997-03-01), Goodfellow et al.
patent: 5610285 (1997-03-01), Lebing et al.
patent: 5614555 (1997-03-01), Nakai et al.
patent: 5616693 (1997-04-01), Hwang et al.
patent: 5618792 (1997-04-01), Gyorkos et al.
patent: 5622984 (1997-04-01), Nakai et al.
patent: 5635593 (1997-06-01), Cheronis et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5663416 (1997-09-01), Kirschenheuter et al.
patent: 5665589 (1997-09-01), Harris et al.
patent: 5700779 (1997-12-01), Goodfellow et al.
patent: 5710026 (1998-01-01), Sprecher
patent: 5712117 (1998-01-01), Sprecher
patent: 5747645 (1998-05-01), Sprecher
patent: 5750506 (1998-05-01), Goodfellow et al.
patent: 5759548 (1998-06-01), Bathurst et al.
patent: 5780009 (1998-07-01), Karatzas et al.
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 5798442 (1998-08-01), Gallant et al.
patent: 5801148 (1998-09-01), Gyorkos et al.
patent: 5807829 (1998-09-01), Gyorkos et al.
patent: 5811241 (1998-09-01), Goodfellow et al.
patent: 5817484 (1998-10-01), Yu et al.
patent: 5834431 (1998-11-01), Stewart et al.
patent: 5843900 (1998-12-01), Cheronis et al.
patent: 5849863 (1998-12-01), Stewart et al.
patent: 5861299 (1999-01-01), Archibald et al.
patent: 5861380 (1999-01-01), Gyorkos et al.
patent: 5863899 (1999-01-01), Cheronis et al.
patent: 5869455 (1999-02-01), Gyorkos et al.
patent: 5874424 (1999-02-01), Batchelor et al.
patent: 5874585 (1999-02-01), Gyorkos et al.
patent: 5891852 (1999-04-01), Gyorkos et al.
patent: 6022969 (2000-02-01), Rice et al.
patent: 6110949 (2000-08-01), Villhauer
patent: 6124257 (2000-09-01), Lezdey et al.
patent: 6313117 (2001-11-01), Bekkali et al.
patent: 6566331 (2003-05-01), Lezdey et al.
patent: 2002/0049164 (2002-04-01), Demuth et al.
patent: 2002/0058809 (2002-05-01), Emmanuel et al.
patent: 2004/0220239 (2004-11-01), Shapiro
patent: 2004/0220242 (2004-11-01), Shapiro
patent: 93/18794 (1993-09-01), None
patent: 94/07525 (1994-04-01), None
patent: 95/28422 (1995-10-01), None
patent: 95/34538 (1995-12-01), None
patent: 96/12021 (1996-04-01), None
patent: 96/14067 (1996-05-01), None
patent: 97/03679 (1997-02-01), None
patent: 97/09346 (1997-03-01), None
patent: 97/09347 (1997-03-01), None
patent: 97/10222 (1997-03-01), None
patent: 97/10231 (1997-03-01), None
patent: 97/21690 (1997-06-01), None
patent: 97/24339 (1997-07-01), None
patent: 97/31937 (1997-09-01), None
patent: 97/33996 (1997-09-01), None
patent: 97/37969 (1997-10-01), None
patent: 97/45402 (1997-12-01), None
patent: 97/48706 (1997-12-01), None
patent: 97/49679 (1997-12-01), None
patent: 98/06417 (1998-02-01), None
patent: 98/09206 (1998-03-01), None
patent: 98/20034 (1998-05-01), None
patent: 98/21186 (1998-05-01), None
patent: 98/22098 (1998-05-01), None
patent: 98/22619 (1998-05-01), None
patent: 98/23565 (1998-06-01), None
patent: 98/24806 (1998-06-01), None
patent: 98/46597 (1998-10-01), None
patent: 98/49190 (1998-11-01), None
patent: 98/50342 (1998-11-01), None
patent: 98/50420 (1998-11-01), None
patent: 98/56821 (1998-12-01), None
patent: 99/41231 (1999-08-01), None
patent: 99/43308 (1999-09-01), None
patent: 00/44390 (2000-08-01), None
patent: 00/52034 (2000-09-01), None
Ihse, I., et al., 1976, “Oral trypsin-inhibitor-induced improvement of the exocrine and endocrine pancreatic functions in alloxan diabetic rats”, Scandinavian Journal of Gastroenterology, vol. 11, pp. 363-368.
Nakamura, N., et al. 1980, “Effect of trypsin inhibitor on blood sugar, insulin, and glucagon levels in normal and streptozotocin rats”, Journal of the Kyoto Prefecture University of Medicine, vol. 89, No. 6, pp. 465-470.
Katsura, M., et al., 1992, “Effect of long-term oral administration of trypsin inhibitor on pancreatic exocrine dysfunction in non-insulin dependent diabetes mellitus (NIDDM)”, Journal of Pancreas, vol. 7, No. 2, pp. 1-8.
Katsura, M., et al., 1992, Journal of Pancreas, English Translation, 23 pages.
Shimoda, I., et al., 1993, “Physiological characteristics of spontaneously developed diabetes in male WBN/Kob rat and prevention of development of diabetes by chronic oral administration of synthetic trypsin inhibitor (FOY-305)”, Pancreas, vol. 8, No. 2, pp. 196-203.
Ikeda, T., et al., 1996, “An inhibition of urinary albumin excretion by protease inhibitor in streptozotocin-diabetic rats”, Nephron, vol. 74, No. 4, pp. 709-712.
Kurtz, T.W., et al., 1988, “Transcription-modulating drugs: A new frontier in the treatment of essential hypertension”, Hypertension, vol. 32, No. 3, pp. 380-386.
Ebeling, P., et al., 1999, “Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes”, Diabetologia, vol. 42, No. 12, pp. 1433-1438.
Davis, S.N., et al., 1999, “Insulin use in the elderly”, Journal of Geriatric Drug Therapy, vol. 12, No. 2, pp. 61-81.
Adelman S.F. et al., “Protease inhibitors suppress fibrinolytic activity of herpesvirus-transformed cells”, J Gen Virol, 1982, 60(Pt 1):15-24.
Altieri, D.C. J Leukoc Biol 1995, 58, pp. 120-127.
Ancliff, P.J., et al., 2001, “Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease”, Blood, vol. 98, pp. 2645-2650.
Anderson Ed, Thomas L, Hayflick Js, Thomas G., “Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant”, J Biol Chem, 268(33):24887-91 (Nov. 25, 1993).
Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H. Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type I in vitro and in vivo. Antimicrob Agents Chemother Apr. 1995;39(4):846-9.
Aprikyan, A.A.G., et al., 2001, “Mutations in the neutrophil elastase gene in cyclic and congenital neutropenia”, Current Opinion in Immunology, vol. 13, pp. 535-538.
Auerswald et al., “K15R M52E) aprotinin is a weak Kunitz-type inhibitor of HIV-1 replication in H
BioHolding, Inc.
Faegre & Benson LLP
Moore William W
Rao Manjunath
LandOfFree
Methods and compositions for treating diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261385